CA2555233A1 - A wound healing composition comprising living dermal fibroblast cells and a fibrin support matrix - Google Patents
A wound healing composition comprising living dermal fibroblast cells and a fibrin support matrix Download PDFInfo
- Publication number
- CA2555233A1 CA2555233A1 CA002555233A CA2555233A CA2555233A1 CA 2555233 A1 CA2555233 A1 CA 2555233A1 CA 002555233 A CA002555233 A CA 002555233A CA 2555233 A CA2555233 A CA 2555233A CA 2555233 A1 CA2555233 A1 CA 2555233A1
- Authority
- CA
- Canada
- Prior art keywords
- wound healing
- expression
- cells
- composition
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 214
- 230000029663 wound healing Effects 0.000 title claims abstract description 157
- 239000011159 matrix material Substances 0.000 title claims abstract description 121
- 210000002950 fibroblast Anatomy 0.000 title claims description 105
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims description 65
- 108010073385 Fibrin Proteins 0.000 title claims description 62
- 102000009123 Fibrin Human genes 0.000 title claims description 62
- 229950003499 fibrin Drugs 0.000 title claims description 62
- 230000002500 effect on skin Effects 0.000 title claims description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 146
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 105
- 108010035532 Collagen Proteins 0.000 claims abstract description 56
- 102000008186 Collagen Human genes 0.000 claims abstract description 56
- 229920001436 collagen Polymers 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 48
- 206010052428 Wound Diseases 0.000 claims abstract description 41
- 108010025325 ribosomal protein L32 Proteins 0.000 claims abstract description 41
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 39
- 108010025614 Apolipoproteins D Proteins 0.000 claims abstract description 24
- 102000009333 Apolipoprotein D Human genes 0.000 claims abstract description 23
- 206010040882 skin lesion Diseases 0.000 claims abstract description 12
- 231100000444 skin lesion Toxicity 0.000 claims abstract description 12
- 102000007469 Actins Human genes 0.000 claims abstract description 8
- 108010085238 Actins Proteins 0.000 claims abstract description 8
- 102000005741 Metalloproteases Human genes 0.000 claims abstract description 8
- 108010006035 Metalloproteases Proteins 0.000 claims abstract description 8
- 210000002460 smooth muscle Anatomy 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 189
- 230000000694 effects Effects 0.000 claims description 50
- 102100040768 60S ribosomal protein L32 Human genes 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 108010049003 Fibrinogen Proteins 0.000 claims description 29
- 102000008946 Fibrinogen Human genes 0.000 claims description 29
- 229940012952 fibrinogen Drugs 0.000 claims description 29
- 108090000190 Thrombin Proteins 0.000 claims description 26
- 238000011161 development Methods 0.000 claims description 26
- 229960004072 thrombin Drugs 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 238000005266 casting Methods 0.000 claims description 19
- 238000003752 polymerase chain reaction Methods 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 15
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims description 14
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims description 14
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims description 14
- 210000003491 skin Anatomy 0.000 claims description 14
- 108010039627 Aprotinin Proteins 0.000 claims description 12
- 229960004405 aprotinin Drugs 0.000 claims description 12
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 12
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims description 11
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 11
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 11
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 11
- 101150000187 PTGS2 gene Proteins 0.000 claims description 10
- 101150022345 GAS6 gene Proteins 0.000 claims description 9
- 102100035071 Vimentin Human genes 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 9
- 210000002510 keratinocyte Anatomy 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 9
- 229960000401 tranexamic acid Drugs 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 8
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 101001076680 Homo sapiens Insulin-induced gene 1 protein Proteins 0.000 claims description 7
- 102100025887 Insulin-induced gene 1 protein Human genes 0.000 claims description 7
- 108010065472 Vimentin Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 7
- 210000005048 vimentin Anatomy 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 101710088194 Dehydrogenase Proteins 0.000 claims description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 241000699802 Cricetulus griseus Species 0.000 claims description 4
- 108010031318 Vitronectin Proteins 0.000 claims description 4
- 102100035140 Vitronectin Human genes 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000001698 pyrogenic effect Effects 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 229960005356 urokinase Drugs 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 101710198769 40S ribosomal protein S15a Proteins 0.000 claims description 2
- 102100033449 40S ribosomal protein S24 Human genes 0.000 claims description 2
- 102100037663 40S ribosomal protein S8 Human genes 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 2
- 240000008886 Ceratonia siliqua Species 0.000 claims description 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229940023476 agar Drugs 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 230000000642 iatrogenic effect Effects 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 108010033800 ribosomal protein S8 Proteins 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 12
- 230000035876 healing Effects 0.000 abstract description 10
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 230000003902 lesion Effects 0.000 abstract description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 239000003550 marker Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 167
- 239000000047 product Substances 0.000 description 74
- 230000001550 time effect Effects 0.000 description 38
- 230000003993 interaction Effects 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 28
- 239000002609 medium Substances 0.000 description 24
- 238000003860 storage Methods 0.000 description 23
- 230000018109 developmental process Effects 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 18
- 238000000540 analysis of variance Methods 0.000 description 18
- 230000004044 response Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 15
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 13
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 229940033618 tisseel Drugs 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 239000004033 plastic Substances 0.000 description 11
- 229920003023 plastic Polymers 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000012384 transportation and delivery Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 230000020764 fibrinolysis Effects 0.000 description 7
- 102000016359 Fibronectins Human genes 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 239000011888 foil Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- 239000000565 sealant Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000003953 foreskin Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000007788 roughening Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108010001781 Apligraf Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 210000000712 G cell Anatomy 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 3
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
- -1 Okinaxobin Proteins 0.000 description 3
- 102000001938 Plasminogen Activators Human genes 0.000 description 3
- 108010001014 Plasminogen Activators Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000013411 master cell bank Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229940127126 plasminogen activator Drugs 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 101150096316 5 gene Proteins 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010027612 Batroxobin Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- OLKBSENZVSADHB-UHFFFAOYSA-N 2,3-dihydroxypropanal non-3-en-2-one Chemical compound CC(C=CCCCCC)=O.O=CC(O)CO OLKBSENZVSADHB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010023728 Alloderm Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 101000885147 Enterococcus avium D-arabitol-phosphate dehydrogenase Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000033182 PLCG2-associated antibody deficiency and immune dysregulation Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 101150061207 RPL32 gene Proteins 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 101710094292 Venom serine protease Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 101150042435 Xrcc1 gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010054176 apotransferrin Proteins 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 108010038522 calobin Proteins 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000000173 fibrin polymerisation Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108010056533 gabonase Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 108010090374 matriderm Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000000019 pro-fibrinolytic effect Effects 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229940000207 selenious acid Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 108020002447 serine esterase Proteins 0.000 description 1
- 102000005428 serine esterase Human genes 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403226.4 | 2004-02-13 | ||
| GB0403226A GB0403226D0 (en) | 2004-02-13 | 2004-02-13 | Means of packaging a wound healing composition |
| GB0403220A GB0403220D0 (en) | 2004-02-13 | 2004-02-13 | Wound healing composition |
| GB0403220.7 | 2004-02-13 | ||
| US55615504P | 2004-03-25 | 2004-03-25 | |
| US55619404P | 2004-03-25 | 2004-03-25 | |
| US60/556,194 | 2004-03-25 | ||
| US60/556,155 | 2004-03-25 | ||
| GB0426252A GB0426252D0 (en) | 2004-11-30 | 2004-11-30 | Wound healing composition |
| GB0426252.3 | 2004-11-30 | ||
| US63242504P | 2004-12-01 | 2004-12-01 | |
| US60/632,425 | 2004-12-01 | ||
| PCT/GB2005/000511 WO2005079821A1 (en) | 2004-02-13 | 2005-02-14 | Wound healing profile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2555233A1 true CA2555233A1 (en) | 2005-09-01 |
Family
ID=34891423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002555233A Abandoned CA2555233A1 (en) | 2004-02-13 | 2005-02-14 | A wound healing composition comprising living dermal fibroblast cells and a fibrin support matrix |
| CA2556098A Expired - Fee Related CA2556098C (en) | 2004-02-13 | 2005-02-14 | Wound healing composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2556098A Expired - Fee Related CA2556098C (en) | 2004-02-13 | 2005-02-14 | Wound healing composition |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8765169B2 (enExample) |
| EP (2) | EP1718317A1 (enExample) |
| JP (4) | JP5706058B2 (enExample) |
| AU (2) | AU2005215213C1 (enExample) |
| CA (2) | CA2555233A1 (enExample) |
| WO (2) | WO2005079821A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
| US8779053B2 (en) | 2003-08-25 | 2014-07-15 | Dow Global Technologies Llc | Coating compositions |
| US8722787B2 (en) | 2003-08-25 | 2014-05-13 | Dow Global Technologies Llc | Coating composition and articles made therefrom |
| US9169406B2 (en) | 2003-08-25 | 2015-10-27 | Dow Global Technologies Llc | Coating compositions |
| US8946329B2 (en) | 2003-08-25 | 2015-02-03 | Dow Global Technologies Llc | Coating compositions |
| US11298453B2 (en) | 2003-10-28 | 2022-04-12 | Smith & Nephew Plc | Apparatus and method for wound cleansing with actives |
| AU2005215213C1 (en) | 2004-02-13 | 2011-04-28 | Smith & Nephew Orthopaedics Ag | Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds |
| GB0508531D0 (en) | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with ultrasound |
| US7753894B2 (en) | 2004-04-27 | 2010-07-13 | Smith & Nephew Plc | Wound cleansing apparatus with stress |
| GB0409446D0 (en) | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
| CN100402097C (zh) * | 2006-07-24 | 2008-07-16 | 暨南大学 | 琼脂/胶原皮肤创伤修复敷料及其制备方法和应用 |
| FR2917629B1 (fr) * | 2007-06-22 | 2009-09-11 | Oreal | Utilisation cosmetique de proteines de type apolipoproteine d |
| WO2009045543A1 (en) * | 2007-10-04 | 2009-04-09 | The Regents Of The University Of California | Treatment of conditions related to shock |
| GB2457870A (en) | 2007-12-21 | 2009-09-02 | Intercytex Ltd | Wound Dressing Applicator |
| US8580314B2 (en) * | 2008-11-04 | 2013-11-12 | Stratatech Corporation | Dried and irradiated skin equivalents for ready use |
| WO2011023843A2 (es) * | 2009-08-25 | 2011-03-03 | Servicio Andaluz De Salud | Elaboración de tejidos artificiales mediante ingeniería tisular utilizando biomateriales de fibrina y agarosa |
| EP2621521A4 (en) | 2010-10-02 | 2014-04-23 | Univ California | MINIMIZING DARMDYS FUNCTIONS |
| WO2012085298A1 (es) * | 2010-12-22 | 2012-06-28 | Universidad De Valladolid (40%) | Gel de fibrina que contiene células del limbo esclerocorneal y su uso en bioingeniería de la superficie ocular |
| FR2999083B1 (fr) * | 2012-12-12 | 2015-01-23 | Univ Nantes | Pansement contenant des fibroblastes et des keratinocytes foetaux |
| CN110551424B (zh) | 2012-12-28 | 2022-07-29 | 陶氏环球技术有限责任公司 | 涂料组合物和由其制成的物品 |
| BR112015015408B1 (pt) | 2012-12-28 | 2021-07-20 | Dow Global Technologies Llc | Composição de revestimento, e, artigo revestido |
| RU2015152082A (ru) | 2013-05-10 | 2017-06-16 | СМИТ ЭНД НЕФЬЮ ПиЭлСи | Соединитель для текучей среды для орошения и аспирации ран |
| US20160213714A1 (en) * | 2015-01-23 | 2016-07-28 | Everon Biosciences, Inc. | Induction of cellular senescence for tissue therapies |
| GB201504124D0 (en) | 2015-03-11 | 2015-04-22 | Proqr Therapeutics B V | Oligonucleotides |
| RU2657202C1 (ru) * | 2017-06-13 | 2018-06-08 | Государственное бюджетное учреждение здравоохранения "Научно-исследовательский институт - краевая клиническая больница имени профессора С.В. Очаповского" Министерства Здравоохранения Краснодарского края (ГБУЗ "НИИ-ККБ N 1 им. проф. Очаповского" Минздрава Краснодарского края | Способ кожной аутопластики |
| RU2702152C1 (ru) * | 2018-11-15 | 2019-10-04 | Государственное бюджетное учреждение здравоохранения "Научно-исследовательский институт - краевая клиническая больница N 1 имени профессора С.В. Очаповского" Министерства здравоохранения Краснодарского края (ГБУЗ "НИИ-ККБ N 1 им. проф. Очаповского" Минздрава Краснодарского края) | Способ лечения донорской раны живота |
| US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
| CN111614010B (zh) * | 2020-05-12 | 2021-04-13 | 中国长江电力股份有限公司 | 500kV焊接型GIL管道母线分解检修方法 |
| JP7486227B2 (ja) * | 2020-06-30 | 2024-05-17 | 株式会社 レオロジー機能食品研究所 | 皮膚改善用組成物 |
| CN113967128B (zh) * | 2020-07-24 | 2023-04-25 | 烟台蓝创生物技术有限公司 | 一种去除海藻酸盐敷料中热原的方法 |
| US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU615414B2 (en) | 1986-04-18 | 1991-10-03 | Marrow-Tech Incorporated | Process for replicating bone marrow |
| US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| FR2597499A1 (fr) | 1986-04-18 | 1987-10-23 | Merieux Inst | Procede de culture microbiologique sur supports de collagene, supports pour ce procede et produits obtenus |
| US4837379A (en) | 1988-06-02 | 1989-06-06 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods for preparation thereof |
| US7208179B1 (en) * | 1990-11-27 | 2007-04-24 | The American National Red Cross | Methods for treating disease and forming a supplemented fibrin matrix |
| DE4127570A1 (de) | 1991-08-21 | 1993-02-25 | Battelle Institut E V | Verfahren zur lokalen antibakteriellen therapie von wunden |
| RU2023424C1 (ru) | 1993-01-13 | 1994-11-30 | Научно-производственный центр трансплантации и культивирования тканей | Способ лечения раны |
| US5591444A (en) | 1995-07-28 | 1997-01-07 | Isolagen Technologies, Inc. | Use of autologous dermal fibroblasts for the repair of skin and soft tissue defects |
| AU6661698A (en) | 1997-02-20 | 1998-09-09 | Gregory S. Keller | Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects |
| JP3333108B2 (ja) | 1997-04-08 | 2002-10-07 | 学校法人東海大学 | 上皮性組織移植片およびその製造方法 |
| AU8224598A (en) | 1997-06-26 | 1999-01-19 | Smith & Nephew Plc | Cell culture products |
| US6150505A (en) * | 1997-09-19 | 2000-11-21 | Hadasit Medical Research Services & Development Ltd. | Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII |
| EP1056413A4 (en) | 1998-02-27 | 2003-08-20 | Bioelastics Res Ltd | INJECTABLE IMPLANTS FOR TISSUE ENHANCEMENT AND RESTORATION |
| AU3118499A (en) | 1998-04-03 | 1999-10-25 | Beth Israel Deaconess Medical Center | Soft tissue reconstructor and method of use |
| US6432710B1 (en) | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
| JP4606583B2 (ja) | 1998-06-05 | 2011-01-05 | オルガノジェネシス インク． | 生物工学的手法による平面シート状移植補綴 |
| US6699287B2 (en) | 1998-09-24 | 2004-03-02 | Korea Atomic Energy Research Institute | Dermal scaffold using alkaline pre-treated chitosan matrix or alkaline pre-treated chitosan and alkaline pre-treated collagen mixed matrix |
| US6124522A (en) | 1998-11-24 | 2000-09-26 | Schroeder; Mark R. | Packaging for adhesive-sided articles to allow one-handed application |
| EP1137380B1 (en) | 1998-11-25 | 2004-03-31 | Coloplast A/S | A layered product ready for non-touch application and a method for producing such a product |
| RU2195889C2 (ru) | 1999-05-24 | 2003-01-10 | Парамонов Борис Алексеевич | Способ дермабразии |
| US6733530B1 (en) | 1999-08-02 | 2004-05-11 | Eric Sun-Yin Chan | Material and method for engraftment of a composite biocompatible skin graft on the neodermis of artificial skin |
| US6699470B1 (en) | 1999-10-12 | 2004-03-02 | Massachusetts Institute Of Technology | Mesh-gel constructs for cell delivery containing enzymes and/or enzyme inhibitors to control gel degradation |
| WO2001032129A2 (en) | 1999-11-05 | 2001-05-10 | Gerigene Medical Corporation | Augmentation and repair of age-related soft tissue defects |
| US6623728B2 (en) * | 2000-06-30 | 2003-09-23 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Cosmetic skin care compositions and containing gum mastic |
| DE10041468C1 (de) * | 2000-08-23 | 2002-03-07 | Surface Care Gmbh | Hautmatrix zur Abdeckung und Regenerierung verletzter Hautpartien sowie Verfahren zu ihrer Herstellung |
| US7144729B2 (en) | 2000-09-01 | 2006-12-05 | Dfb Pharmaceuticals, Inc. | Methods and compositions for tissue regeneration |
| AU9109201A (en) * | 2000-09-18 | 2002-03-26 | Organogenesis Inc | Methods for treating a patient using a bioengineered flat sheet graft prostheses |
| ES2173812B1 (es) | 2001-03-01 | 2003-12-16 | Ct Investig Energeticas Ciemat | Dermis artificial y metodo de obtencion. |
| GB0105899D0 (en) * | 2001-03-09 | 2001-04-25 | Intercytex Ltd | Fibrosis reduction treatment |
| DE10116362A1 (de) * | 2001-04-02 | 2002-10-10 | Biotissue Technologies Ag | Zwei-Komponenten Zusammensetzungen zur in situ Herstellung v. Fibroblasten und Keratinozyten umfassenden Zelltransplantaten |
| US20030069639A1 (en) | 2001-04-14 | 2003-04-10 | Tom Sander | Methods and compositions for repair or replacement of joints and soft tissues |
| US20040031067A1 (en) * | 2001-10-11 | 2004-02-12 | Meenhard Herlyn | Regulation of human skin healing |
| US20030166274A1 (en) | 2001-11-15 | 2003-09-04 | Hewitt Charles W. | Three-dimensional matrix for producing living tissue equivalents |
| WO2003084385A2 (en) | 2002-04-02 | 2003-10-16 | William Marsh Rice University | Redifferentiated cells for repairing cartilage defects |
| DE10217779A1 (de) | 2002-04-18 | 2003-11-13 | Co Don Ag | Konservierte Gewebematrix eines Hohlorganes, insbesondere eines Blutgefäßes, Verfahren zur Herstellung und Verwendung dieser |
| US20040082063A1 (en) | 2002-10-18 | 2004-04-29 | Reliance Life Sciences Pvt. Ltd. | Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture |
| AU2005215213C1 (en) | 2004-02-13 | 2011-04-28 | Smith & Nephew Orthopaedics Ag | Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds |
| RU2273457C2 (ru) | 2004-06-01 | 2006-04-10 | Сергей Степанович Кузнецов | Способ лечения грыж передней брюшной стенки |
-
2005
- 2005-02-14 AU AU2005215213A patent/AU2005215213C1/en not_active Ceased
- 2005-02-14 CA CA002555233A patent/CA2555233A1/en not_active Abandoned
- 2005-02-14 EP EP05708330A patent/EP1718317A1/en not_active Withdrawn
- 2005-02-14 WO PCT/GB2005/000511 patent/WO2005079821A1/en not_active Ceased
- 2005-02-14 WO PCT/GB2005/000523 patent/WO2005079822A2/en not_active Ceased
- 2005-02-14 CA CA2556098A patent/CA2556098C/en not_active Expired - Fee Related
- 2005-02-14 EP EP05764678.8A patent/EP1718318B1/en not_active Expired - Lifetime
- 2005-02-14 US US10/589,150 patent/US8765169B2/en not_active Expired - Fee Related
- 2005-02-14 JP JP2006552692A patent/JP5706058B2/ja not_active Expired - Fee Related
- 2005-02-14 US US10/589,227 patent/US9526746B2/en not_active Expired - Fee Related
- 2005-02-14 AU AU2005215211A patent/AU2005215211B2/en not_active Ceased
-
2012
- 2012-06-14 JP JP2012135016A patent/JP6141603B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-15 US US14/279,057 patent/US9248153B2/en not_active Expired - Fee Related
- 2014-12-22 JP JP2014258639A patent/JP6141821B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-02 JP JP2015075997A patent/JP2015134815A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2556098A1 (en) | 2005-09-01 |
| AU2005215213C1 (en) | 2011-04-28 |
| WO2005079822A2 (en) | 2005-09-01 |
| WO2005079822A3 (en) | 2005-11-03 |
| US9526746B2 (en) | 2016-12-27 |
| AU2005215211B2 (en) | 2011-11-03 |
| AU2005215211A1 (en) | 2005-09-01 |
| JP2015063555A (ja) | 2015-04-09 |
| US9248153B2 (en) | 2016-02-02 |
| EP1718318A2 (en) | 2006-11-08 |
| JP6141603B2 (ja) | 2017-06-07 |
| US20140335183A1 (en) | 2014-11-13 |
| WO2005079821A1 (en) | 2005-09-01 |
| JP6141821B2 (ja) | 2017-06-07 |
| EP1718317A1 (en) | 2006-11-08 |
| JP2015134815A (ja) | 2015-07-27 |
| JP2012192206A (ja) | 2012-10-11 |
| US20080193507A1 (en) | 2008-08-14 |
| JP2007522195A (ja) | 2007-08-09 |
| US20080226720A1 (en) | 2008-09-18 |
| JP5706058B2 (ja) | 2015-04-22 |
| US8765169B2 (en) | 2014-07-01 |
| CA2556098C (en) | 2015-11-24 |
| EP1718318B1 (en) | 2014-08-13 |
| AU2005215213B2 (en) | 2010-09-09 |
| AU2005215213A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9248153B2 (en) | Wound healing profile | |
| Gille et al. | Migration pattern, morphology and viability of cells suspended in or sealed with fibrin glue: a histomorphologic study | |
| Galassi et al. | In vitro reconstructed dermis implanted in human wounds: degradation studies of the HA-based supporting scaffold | |
| US20210187036A1 (en) | Method of Tissue Repair | |
| EP2603247B1 (en) | Fibrin based scaffold, preparation and use thereof | |
| Bilic et al. | Human preterm amnion cells cultured in 3-dimensional collagen I and fibrin matrices for tissue engineering purposes | |
| EP1861492B1 (en) | Skin equivalent culture | |
| Klewin-Steinböck et al. | Effect of injectable equine collagen type I on metabolic activity and apoptosis of gingival fibroblasts | |
| Zhao et al. | Photopolymerizable fish collagen peptide-GelMa composite hydrogels for dental pulp regeneration | |
| Al-Muhairi | A prospective, multicentre, randomized, controlled clinical investigation of dermagraft in patients with venous leg ulcers | |
| Jones | Monitoring the Effects of MMP Inhibitors on Extracellular Matrix Degradation for use in Implant Protection | |
| Bilic | Sealing and healing of fetal membranes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20190214 |